PEG-MGF — PEGylated Mechano Growth Factor | Research Compound

🧪

Laboratory Research Compound — For In Vitro Use Only
This compound is supplied by RS Bio Labs solely as a laboratory research material for use by qualified scientific personnel in in vitro research settings. It is NOT approved, intended, or authorised for human consumption, self-administration, diagnostic, therapeutic, or veterinary use of any kind. All research findings referenced on this page are from preclinical models (cell culture, animal studies) unless explicitly stated otherwise. Preclinical data does not establish safety or efficacy in humans. RS Bio Labs makes no medical or health claims.

Mechanism of Action

MGF is the product of alternative splicing of the IGF-1 gene in response to mechanical loading or tissue damage. The full MGF protein contains the standard IGF-1 mature peptide plus a unique 24-amino-acid C-terminal "E-domain" extension. Research has established that the E-domain peptide itself — independent of the IGF-1 portion — is the functionally distinctive component, signalling through a yet-uncharacterised receptor pathway separate from the IGF-1 receptor.

The principal documented biological activity is activation and proliferation of muscle satellite cells (skeletal-muscle progenitor cells responsible for repair after damage). MGF's natural role appears to be the rapid mobilisation of the satellite pool in the early phase of muscle repair, followed by the slower-acting systemic IGF-1Ea isoform that drives the subsequent hypertrophy and remodelling.

PEGylation conjugates the E-domain peptide to polyethylene glycol, extending half-life from minutes (native MGF) to days (PEG-MGF). This extension is what makes PEG-MGF tractable as a research probe; native MGF's very brief plasma life makes systematic dose-response work difficult outside local-injection protocols.

Mechano-Responsive Splice Variant

MGF arises from alternative splicing of the IGF-1 gene in mechanically-loaded or damaged skeletal muscle — a local, transient signal distinct from circulating IGF-1.

Satellite Cell Mobilisation

The 24-aa C-terminal E-domain peptide activates and proliferates satellite cells (muscle progenitors), mobilising the repair pool in the early phase of post-damage remodelling.

PEG Half-Life Extension

PEG conjugation extends plasma half-life from ~7 minutes (native MGF) to 48–72 hours (PEG-MGF) — making systematic research dose-response work tractable.

Splice-Variant Biology Research

Foundational research from Geoffrey Goldspink and colleagues at University College London characterised MGF as a mechanically-responsive IGF-1 splice variant in the late 1990s. Subsequent work documented that the E-domain peptide alone — without the IGF-1 mature sequence — retains the satellite-cell activation activity, leading to research focus on the isolated E-domain.

The signalling pathway remains incompletely characterised — published work suggests a receptor distinct from the IGF-1 receptor, but the canonical receptor has not been identified. This is the principal open question in MGF molecular pharmacology.

Skeletal Muscle Repair Research

Preclinical muscle-injury research has documented enhanced satellite-cell proliferation and accelerated repair markers with E-domain peptide dosing. Models of muscular dystrophy, age-related sarcopenia and acute muscle injury have all been explored.

Research has also examined MGF in cardiac repair contexts (the heart has its own satellite-cell-equivalent population responsive to mechanical loading) and in cartilage repair models. The compound's research profile is broader than the skeletal-muscle research focus implies.

Key Published Research

Mechano Growth Factor: A Splice Variant of IGF-1 Regulated by Muscle Activity

The Journal of Physiology · Yang, Alnaqeeb, Simpson & Goldspink · 1996

Foundational paper characterising MGF as a mechanically-responsive splice variant of IGF-1. Documented the alternative splicing event, the unique E-domain, and the temporal pattern of expression following muscle loading — establishing the entire MGF research field.

The E-Domain Peptide of MGF Is Active Independent of the IGF-1 Mature Sequence

FEBS Letters · Mills et al. · 2007

Demonstrated that the isolated 24-amino-acid E-domain peptide retains satellite-cell activation activity in cell culture, independent of the IGF-1 mature sequence. Established the rationale for research focused on the E-domain peptide alone rather than the full MGF protein.

Mechano Growth Factor and Skeletal Muscle Repair

Cell and Tissue Research · 2010

Review of MGF's role in skeletal muscle repair, satellite-cell biology and the broader context of IGF-1 splice variants. Documents the local-vs-systemic distinction between MGF and IGF-1Ea and the research applications across muscular dystrophy and age-related sarcopenia models.

Research Context: PEG-MGF is an unregulated research compound. It has not been approved by the MHRA, FDA or any other regulatory authority. WADA-prohibited in competitive sport. RS Bio Labs supplies it as a research-grade laboratory compound for in vitro scientific research only — not for human consumption, self-administration, veterinary use, or therapeutic application. This profile is for educational and scientific reference only.